Literature DB >> 11982699

Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure.

Eiichiro Yumoto1, Toshihiro Higashi, Kazuhiro Nouso, Harushige Nakatsukasa, Keishi Fujiwara, Tadashi Hanafusa, Yasuhiro Yumoto, Tadao Tanimoto, Masashi Kurimoto, Noriaki Tanaka, Takao Tsuji.   

Abstract

BACKGROUND AND AIMS: The aim was to determine the role of T-helper (Th)1/Th2 cytokine responses in the clinical outcome of patients with acute liver injury.
METHODS: The serum levels of the cytokines, interleukin (IL)-18, gamma-interferon (IFN-gamma), IL-10 and IL-4 were measured in 20 fulminant hepatic failure (FHF), 18 acute hepatitis (AH), 30 chronic viral hepatitis and 20 liver cirrhosis (LC) patients. Thirteen cases were from the intensive care unit (ICU) and there were 21 healthy volunteers. Immunohistochemical staining of liver biopsies for IL-18 expression was also performed.
RESULTS: Serum IL-18 levels in patients with FHF were significantly more elevated than in patients with other liver diseases, ICU cases and healthy volunteers. Furthermore, serum IFN-gamma levels in patients with FHF were also significantly higher than in patients with chronic viral hepatitis, LC and healthy volunteers. We found a positive correlation between the levels of IL-18 and IFN-gamma. However, no relationship was observed between these and clinical outcome. In immunohistochemical staining, CD68+ macrophage cells and IL-18-positive cells were observed in portal zones. Elevated serum IL-10 levels were restricted to patients presenting with FHF, and were significantly higher in surviving cases (P < 0.01). Furthermore, serum IL-10 levels, but not IL-4 levels, were inversely correlated with serum total bilirubin concentrations (P = 0.045) and the death rate (p) outlined in Japan (P = 0.030).
CONCLUSION: These results suggest that IL-18 and IFN-gamma are involved in the pathogenesis of acute hepatic injury in humans, and that, in particular, elevated serum levels of IL-10 may be predictive of improved outcomes for these patients. Copyright 2002 Blackwell Science Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11982699     DOI: 10.1046/j.1440-1746.2002.02690.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  22 in total

1.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 2.  Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells.

Authors:  Antoine Monsel; Ying-Gang Zhu; Stephane Gennai; Qi Hao; Jia Liu; Jae W Lee
Journal:  Anesthesiology       Date:  2014-11       Impact factor: 7.892

Review 3.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

4.  Altered immune function of monocytes in different stages of patients with acute on chronic liver failure.

Authors:  T Xing; L Li; H Cao; J Huang
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Authors:  Masahiro Shinoda; Arno W Tilles; Go Wakabayashi; Atsushi Takayanagi; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  Tissue Eng       Date:  2006-05

6.  Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha.

Authors:  He YingLi; Lin Shumei; Yang Qian; Chen Tianyan; Zhao Yingren; Chen Wei
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

7.  IP-10 protects while MIP-2 promotes experimental anesthetic hapten - induced hepatitis.

Authors:  Dolores B Njoku; Zhaoxia Li; Jenelle L Mellerson; Rajni Sharma; Monica V Talor; Nicole Barat; Noel R Rose
Journal:  J Autoimmun       Date:  2009-01-07       Impact factor: 7.094

8.  Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo.

Authors:  S Finotto; J Siebler; M Hausding; M Schipp; S Wirtz; S Klein; M Protschka; A Doganci; H A Lehr; C Trautwein; R Khosravi-Far; D Strand; A Lohse; P R Galle; M Blessing; M F Neurath; R Khosravi-Fahr
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

9.  Quercetin Protects Mice from ConA-Induced Hepatitis by Inhibiting HMGB1-TLR Expression and Down-Regulating the Nuclear Factor Kappa B Pathway.

Authors:  Xi Li; Hong-Chun Liu; Qun-Yan Yao; Bei-Li Xu; Shun-Cai Zhang; Chuan-Tao Tu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

Review 10.  Circulating endothelial progenitor cells: a new approach to anti-aging medicine?

Authors:  Nina A Mikirova; James A Jackson; Ron Hunninghake; Julian Kenyon; Kyle W H Chan; Cathy A Swindlehurst; Boris Minev; Amit N Patel; Michael P Murphy; Leonard Smith; Doru T Alexandrescu; Thomas E Ichim; Neil H Riordan
Journal:  J Transl Med       Date:  2009-12-15       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.